protein mutations in familial hypertrophic cardiomyopathies, we tested the hypothesis that rapamycin's anti-hypertrophy action in the heart is due to direct effects of the drug on myofilament protein function. We found little or no effect of rapamycin (10 -8 -10 -4 M) on maximum Ca 2+ -activated isometric force, while Ca 2+ -sensitivity was increased at some rapamycin concentrations in rabbit skeletal and cardiac, and rat cardiac muscle. At concentrations that increased Ca 2+ -sensitivity of isometric force, rapamycin reversibly inhibited kinetics of isometric tension redevelopment (k TR ) in rabbit skeletal, but not cardiac, muscle. The greatest inhibition (~50%) was at intermediate levels of Ca 2+ -activation, with less inhibition of k TR (~15%) at maximum Ca 2+ activation levels. Rapamycin (10 -7 M) increased F-actin sliding speed (~11%) in motility assays, but inhibited sliding at 10 -5 -10 -4 M. These results indicate that rapamycin has a greater effect on Ca 2+ regulatory proteins of the thin filament than on actomyosin interactions. These effects, however, are not consistent with rapamycin's antihypertrophic activity being mediated through direct effects on myofilament contractility.
INTRODUCTION
Rapamycin (sirolimus) is an antibiotic derived from Streptomyces hygroscopicus that is most commonly used as an immunosuppressant in the treatment of human organ transplant patients. Rapamycin's antigrowth properties may also be clinically useful for cardiovascular problems. Stents impregnated with rapamycin effectively reduce restenosis (Woods and Marks, 2004) . Rapamycin may also prove useful in treating atherosclerosis (Castro et al., 2004) .
Furthermore, in vitro studies with cardiac myocytes show that rapamycin inhibits both protein synthesis and cardiac myocyte hypertrophy (Sadoshima and Izumo, 1995; Boluyt et al., 1997) .
At clinically relevant doses, rapamycin attenuates development of cardiac hypertrophy and regresses established hypertrophy in aortic-banded mice without reducing cardiac function (Shioi et al., 2003; McMullen et al., 2004) . The increase in cardiomyocyte size typically seen in aorticbanded mice is also effectively attenuated by rapamycin. The relevant biochemical pathway(s) affected by rapamycin have not been unambiguously identified; there are several possibilities.
changes in S6K1 phosphorylation and activity. Rapamycin's anti-hypertrophic activity in aorticbanded mice is consistent with inhibition of the PI3K pathway (mTOR) causing suppression of load-induced S6K1 activation (Shioi et al., 2003) . Studies with dnPI3K transgenic mice, however, indicate that the PI3K pathway does not play a role in pathological cardiac hypertrophy induced by aortic banding (McMullen et al., 2003) . While it remains possible that mTOR activation in these studies occurs through PI3K-independent pathways, alternative routes for rapamycin's anti-hypertrophic activity should be considered.
Binding of rapamycin to FKBP12 also alters Ca 2+ transients in myocytes by dissociating regulatory proteins tropomyosin, troponin I and troponin T (Bonne et al., 1998; Fatkin and Graham, 2002) . The signaling pathways by which these mutations trigger the hypertrophic response are unknown. The existence of these disease-causing mutations raises the possibility that rapamycin's anti-hypertrophic effects in cardiac tissue could be due, in part, to a direct effect This article has not been copyedited and formatted. The final version may differ from this version. of rapamycin on the myofilaments and myocyte contractility. Many FHC-related mutations enhance contractility by increasing Ca 2+ -sensitivity of isometric force and/or unloaded sliding speed, and in some instances by also increasing maximum sliding speed (Lin et al., 1996; Sweeney et al., 1998; Homsher et al., 2000; Takahashi-Yanaga et al., 2001; Fatkin and Graham, 2002; Köhler et al., 2003) . Therefore, if rapamycin's anti-hypertrophic activity was mediated in part by direct effects on myofilament proteins, we predicted that rapamycin should have effects opposite to those of FHC mutations: rapamycin would reduce force and/or sliding speed at a
FKBP12 from ryanodine receptors (RyR
given [Ca 2+ ].
In the present study, we explored the acute effects of rapamycin on isometric force and Ca 2+ -sensitivity in skinned skeletal and cardiac muscle, as well as its effects on F-actin sliding speed in the in vitro motility assay. Our data indicate that rapamycin has little or no effect on maximum Ca 2+ -activated force, and inhibits F-actin sliding speed only at high concentrations.
At concentrations where rapamycin affected submaximal force, it increased Ca 2+ -sensitivity.
These results suggest that rapamycin's anti-hypertrophic effects do not involve direct inhibition of the myofilament proteins.
This article has not been copyedited and formatted. The final version may differ from this version. 
Fiber Mechanics
Preparation of single, glycerinated fibers. Single skeletal fiber segments from male New Zealand white rabbit psoas muscles were dissected and prepared for mechanical experiments as described previously (Chase and Kushmerick, 1988; Chase et al., 1994; Regnier et al., 2002) . The bundles were permeabilized with 0.5% Brij 58, then 50% glycerol in skinning solution and were stored at -20°C before use (Regnier et al., 2002) . Trabeculae from male Sprague-Dawley rat hearts and male New Zealand white rabbit hearts were dissected and prepared as described previously for rat cardiac trabeculae (Regnier et al., 2000) . Hearts were excised, and the interior wall of the right ventricle was exposed to relaxing solution containing glycerol (50% v/v) and Triton X-100 (1%) overnight at 4°C. (Unless otherwise indicated, all chemicals used in experiments were supplied by Sigma-Aldrich Co. St. Louis, MO).
Permeabilized cardiac trabeculae were then dissected and stored at 4°C for up to 4 days.
Skeletal fiber ends were chemically fixed by applying glutaraldehyde (5% in H 2 O with 1 mg/ml Na fluorescein added as a visual indicator) from a syringe flow system. The fixed ends were wrapped in aluminum foil T-clips for attachment to the mechanical apparatus via small wire hooks. Fiber segments were mounted on a motor (step time 300 µs) (Aurora Scientific Inc, Ontario, Canada) to control overall fiber length at one end, and on a capacitative-type force transducer (f c = 3.3 kHz; Aurora Scientific Inc, Ontario, Canada) at the other end. The motor and This article has not been copyedited and formatted. The final version may differ from this version. force transducer were located on a modified stage of an inverted microscope (Chase and Kushmerick, 1988) .
Initial sarcomere length (L s ) (measured by helium-neon laser diffraction), fiber length and fiber diameter (measured with an optical micrometer) were measured prior to the start of each experiment. Trabecular L s was set to 2.2 µm at pCa 9.0; skeletal fiber L s was set to 2.6 µm.
Chemical fixation of fiber segment ends and reduced temperature were utilized to maintain integrity of fiber structure and mechanical properties during prolonged activation. Both experimental control systems also employed periodic (0.2 Hz) unloading (i.e., fiber shortening followed by restretch to the isometric length) (Brenner, 1983) .
Solutions. Relaxing and activating solutions were prepared as described previously (Chase and Kushmerick, 1988; Martyn and Gordon, 1988) Woburn, Ma, R-5000) was reconstituted in 100% absolute ethanol and added to the varying pCa solutions for a final concentration of 1% ethanol and specified rapamycin concentration. Final concentrations of rapamycin ranged from 10 -8 M to 10 -4 M. 1% ethanol was present in all solutions to control for possible effects of ethanol alone (Regnier et al., 1996) . Experimental control, data acquisition, and data analysis. Steady-state isometric force and the kinetics of force redevelopment were determined as described previously (Chase et al., 1994; Regnier et al., 2002 ) ( The relation between steady-state, isometric force (F) and pCa was fitted by a nonlinear least-squares regression to the Hill equation:
where F 0 is the maximum force at pCa 5, pCa 50 is the pCa at which F = F 0 /2, and n determines the steepness of the Ca 2+ dependence around pCa 50 .
In vitro Motility Assays
Solutions and Flow Cell Preparation. In vitro motility assays were performed to measure the sliding speed of fluorescently labeled F-actin over heavy meromyosin (HMM) coated surfaces.
This article has not been copyedited and formatted. The final version may differ from this version. Experimental protocols, solution preparation, flow cell preparation, and analysis were essentially as described previously (Chase et al., 2000) . Assays were carried out at 30 o C, with temperature in the flow cell maintained by circulating temperature-controlled water through a copper coil around the objective. Actin and myosin were extracted from New Zealand White Rabbit back and leg muscles. F-actin was fluorescently labeled with rhodamine phalloidin (RhPh). HMM was obtained by mild chymotryptic digestion of myosin. Immediately before the motility assay, 2 mM ATP, 16.7 mM glucose, 100 µg/ml glucose oxidase, 18 µg/ml catalase (Worthington Biochemical Corp., Lakewood, NJ), 0.3% methyl cellulose, and an additional 40 mM DTT were added to actin buffer (AB), composed of 25 mM KCl, 25 mM imidazole, 4 mM MgCl 2 , 1 mM EGTA, 1 mM DTT, at pH 7.4 (Kron et al., 1991) . Glucose, glucose oxidase, catalase and extra DTT were added to minimize photo-bleaching of the RhPh label and photo-oxidative damage to the proteins (Kron et al., 1991; Gordon et al., 1997) . Rapamycin was reconstituted in 100% absolute ethanol, and added to solutions at concentrations of 10 -8 -10 -4 M, with a final concentration of 1% ethanol in all solutions as described for permeabilized muscle preparations.
The negative control AB (no rapamycin added) was prepared with 1% ethanol to control for possible effects of ethanol alone (Regnier et al., 1996) .
Fluorescence Microscopy and Data Acquisition. RhPh labeled F-actin motility was observed by fluorescence microscopy on a Diastar-Reichart microscope at 100X magnification, imaging 6-8 fields from varying areas on the flow cell. Field images were recorded as 30-second clips using a VE1000 SIT camera (Dage-MTI, Inc, Michigan City, IN) and a Panasonic AG-7350 videocassette recorder. The analog clips were digitized using iMovie software as QuickTime files on a Macintosh 2X PowerPC G4 computer using a Miglia video interface (Miglia Technology Ltd., Enfield, UK). RhPh F-actin sliding speed distributions were analyzed This article has not been copyedited and formatted. The final version may differ from this version. in skinned muscle preparations dipped in bathing solutions with varying rapamycin concentrations. Comparisons were made between rat cardiac and rabbit cardiac muscle, and rabbit fast skeletal muscle fibers. The fibers were dipped in pCa 5 bathing solution (no rapamycin) immediately prior to and following each dip in rapamycin solution to identify irreversible effects of rapamycin and normalize against fiber degradation. There was little or no effect of rapamycin (10 -8 to 10 -4 M) on maximum Ca 2+ -activated force in any of the muscle types (Fig. 2) . Given that the inhibitory effects of rapamycin were, at most, small, we chose two concentrations for studies at submaximal Ca 2+ activation: 1 µM, an effective immunosuppressant therapeutic dosage for mice which is comparable to human dosage (Shioi et al., 2003) , and 100 µM, a maximum rapamycin concentration.
Submaximal Ca 2+ activation of isometric force and kinetics of tension redevelopment. To determine the effects of rapamycin on Ca 2+ -activation of isometric force, permeabilized preparations were subjected to three consecutive cycles of increasing Ca 2+ concentrations ranging from pCa 9 to pCa 4.5. The initial control was performed in the absence of rapamycin. Next was a series of measurements with either 1 µM or 100 µM rapamycin.
Finally, a repeat of the control measurements was performed to evaluate reversibility of rapamycin effects and to control for degradation of preparations.
We found that rapamycin increased Ca 2+ -sensitivity of isometric force (leftward shift in the force-pCa relationship, Eq. 1) in some of the experimental conditions studied. In rat cardiac muscle, 100 µM rapamycin increased Ca 2+ -sensitivity by 0.11 pCa units ( Fig. 3C ; whereas there was no effect at 1 µM (data not shown). In rabbit cardiac and skeletal muscle, 1 µM rapamycin increased Ca 2+ -sensitivity by 0.08 or 0.13 pCa units respectively ( Fig. 3A, B ; Table 1 ); interestingly, there was no effect at 100 µM in either rabbit muscle type (data not shown).
The kinetics of isometric tension redevelopment were also studied to gain mechanistic insight into the effects of rapamycin at submaximum Ca 2+ activation (Fig. 1B) . k TR data were obtained from rabbit skeletal and rabbit cardiac muscle preparations. To obtain averages of force and k TR , data were divided into bins according to the normalized isometric force production (Regnier et al., 1996) . Both force and k TR data were normalized to the respective saturating Ca 2+ value for the same fiber. The maximum k TR was 9.80 + 0.47 s -1 for skeletal muscle and was 1.67 + 0.13 s -1 for rabbit cardiac muscle. k TR increased nonlinearly as force was increased by elevated Ca 2+ , although the increase was substantially greater in skeletal muscle than in cardiac (Fig. 4) . In skeletal muscle, 1 µM rapamycin reversibly inhibited k TR at intermediate force levels
under conditions where Ca 2+ -sensitivity of isometric force was increased (Fig. 4A) . At saturating Ca 2+ levels, k TR was inhibited by ~15%, while the maximum inhibition of k TR observed at intermediate force levels was ~50%. In rabbit cardiac muscle, rapamycin had little or no effect on the relationship between k TR and steady-state force (Fig. 4B ).
Unloaded filament sliding speed. We utilized an in vitro motility assay with rabbit skeletal actin and HMM to determine if rapamycin affects unloaded sliding speed of F-actin in the absence of calcium regulatory proteins. This method utilizes purified rabbit skeletal F-actin and HMM, and minimizes the potential effects of internal loads that are present in the intact sarcomere studied with fiber mechanics methods. Over the rapamycin concentration range tested, there was a biphasic effect on the F-actin sliding speed ( 
DISCUSSION
The purpose of the present investigation was to determine if the beneficial effects of the anti-growth drug rapamycin in animal models of cardiac hypertrophy could be due to direct effects of rapamycin on contractile myofilament function. This possibility derives from the identification of myofilament protein mutations that alter contractility and are causal in cardiac hypertrophy. There were two major findings of this study. First, there was little or no effect of rapamycin on actomyosin crossbridge cycling, except for inhibition in unloaded conditions at concentrations above therapeutic levels. Second, Ca 2+ regulation can be altered by rapamycin at therapeutic doses in rabbit tissue, with increased Ca 2+ -sensitivity. Thus, the acute effects of rapamycin on myofilament function are inconsistent with the prediction that the drug's antihypertrophic effects stem from inhibition of cardiac contractility.
Our conclusion that rapamycin either has little effect, or enhances cardiac contractility is in agreement with the in vivo data presented by Shioi et al. (2003) and McMullen et al. (2004) .
Cardiac function of aortic-banded mice was assessed by echocardiography in both studies following administration of rapamycin for 1 week. In mice that were treated with a therapeutic dose of rapamycin prior to and immediately following aortic banding, fractional shortening, and thus the cardiac contractility, was essentially the same in rapamycin-treated and untreated animals (Shioi et al., 2003) . In animals where treatment began one week following aorticbanding induced hypertrophy, rapamycin had little or no effect on hearts from animals exhibiting compensated hypertrophy, while it significantly improved fractional shortening and ejection fraction of hearts from animals exhibiting decompensated hypertrophy (McMullen et al., 2004) .
Actomyosin. Actomyosin interactions were investigated either at maximum Ca regulatory proteins. Our data showed little or no effect of rapamycin on maximum Ca 2+ -activated force (Fig. 2) or on maximum k TR (Fig. 4 , where force ~ 100%). These results indicate that actomyosin crossbridge cycling is not affected by rapamycin under isometric conditions in either steady-state (Fig. 2) or during the approach to steady-state (Fig. 4) . The in vitro motility assay was utilized to determine if rapamycin affects crossbridge cycling under unloaded conditions. The small but significant enhancement of V f at 10 -7 M rapamycin and substantial inhibition at >10 -5 M (Fig. 5) indicate that rapamycin has a greater effect on unloaded actomyosin crossbridge cycling.
There were no apparent species or muscle type differences in the effects of rapamycin on actomyosin cycling. There was no effect on isometric force measured in all three muscle types examined (Fig. 2) . In either the absence or presence of 1 µM rapamycin, rabbit skeletal k TR was almost 6-fold faster than rabbit cardiac at saturating Ca 2+ ; this kinetic difference is expected because these muscle types contain distinct myosin heavy chain isoforms (Bottinelli and Reggiani, 2000) .
Ca
2+ regulation. The possibility that rapamycin interacts with calcium regulatory proteins of the thin filament was investigated by determining steady-state force-pCa relationships ( Fig. 3 and Table 1 ) and the Ca 2+ -dependence of k TR (Fig. 4) in the presence and absence of rapamycin. This is particularly relevant because cardiac muscle functions at submaximum Ca 2+ levels. Thus rapamycin could significantly influence cardiac physiology if it modulates function of the Ca 2+ regulatory proteins, even though there was little or no effect at saturating Ca 2+ .
Rabbit psoas and cardiac preparations showed an increase in Ca 2+ -sensitivity of isometric force at 1 µM rapamycin ( Fig. 3 and Table 1 ). There was no effect on the force-pCa relation in either rabbit preparation at a higher dose (100 µM) (data not shown), which may be related to the biphasic effect on actomyosin cycling observed under unloaded conditions with rabbit skeletal HMM (Fig. 5) . A leftward shift was also seen in rat cardiac trabeculae, but only at the higher rapamycin concentration (100 µM) (Fig. 3 and Table 1 ). These steady-state force data suggest an influence of rapamycin on the thin filament Ca 2+ -regulatory proteins.
This conclusion is substantiated by kinetic data (Fig. 4) . The greatest effect of rapamycin on k TR was found at intermediate force levels obtained at submaximum Ca 2+ in rabbit psoas fibers (Fig. 4a) . k TR measured at submaximum Ca 2+ is an indicator of the dynamics of thin filament regulatory function (Regnier et al., 1996; Regnier et al., 1998) and thus the data in Fig. 4A indicate that rapamycin influences the Ca 2+ -regulatory proteins. The k TR -force relationship in cardiac muscle (Fig. 4b) is not as curvilinear as that for skeletal (Fig. 4a) . This difference between cardiac and skeletal muscle has been reported previously and may be due to differences in kinetics of Ca 2+ dissociation from TnC, or to differences in coupling between Ca 2+ dissociation from TnC and strong crossbridge dissociation from actin (Landesberg and Sideman, 1994; Hancock et al., 1996; Regnier et al., 1996; Regnier et al., 1998 ). Rapamycin's inhibition of the k TR -force relation in cardiac muscle was less than that in skeletal muscle (Fig. 4) , although this may be due, at least in part, to regulatory protein isoform differences that underlie cardiac-skeletal differences in the activation-dependence of k TR .
Mechanism of rapamycin's anti-hypertrophic activity. Rapamycin has the ability to suppress load-induced cardiac hypertrophy in aortic-banded mice (Shioi et al., 2003) and to regress established hypertrophy in the same animal model (McMullen et al., 2004) . These effects were pronounced, with attenuation of both the increase in total heart weight and increase in myocyte cell size. Many signaling pathways affect cardiac function, and therefore contribute to the causes of cardiac hypertrophy (Fatkin and Graham, 2002; Frey and Olson, 2003; Pyle and This article has not been copyedited and formatted. The final version may differ from this version. Solaro, 2004) . Our data show that rapamycin's anti-hypertrophic activity cannot be explained by its acute effects on cardiac (and skeletal) muscle mechanics (Fig. 6 ). This suggests that pathways involving mechano-sensitive signaling molecules, such as those bound to or associated with the Z-disc (red, Fig. 6 Rapamycin's ability to attenuate cardiac hypertrophy in aortic-banded mice, therefore, is not likely through the inhibition of PI3K-dependent activation of mTOR.
Ca 2+ signaling pathways (green, Fig. 6 ) under control of calcineurin have also been
shown to be involved in cardiac hypertrophy (Frey and Olson, 2003) . Rapamycin has been shown to dissociate FKBP12 from the ryanodine receptor, which alters Ca 2+ transients (Su et al., 2003) . This alteration could also play a part in the anti-hypertrophic effects seen with rapamycin treatment, and is consistent with the observed upregulation of calcineurin/NFAT gene expression in aortic-banded mice (Wilkins et al., 2004) . These same arguments might apply to hypertrophy observed in FHC patients. Many FHC mutations occur in the calcium regulatory proteins of the thin filament, and the majority of them cause an increase in Ca 2+ -sensitivity in some aspect of cardiac function (Köhler et al., 2003; Wang et al., 2004 Three force records are superimposed within the graph. Fig. 2 . Effect of rapamycin on maximum Ca 2+ -activated isometric force (pCa 5) in chemically permeabilized preparations from rabbit psoas, and cardiac trabeculae from rabbit and rat. Force in the presence of rapamycin was normalized to the average of that measured before and after.
There was little or no effect of increasing rapamycin concentration on force with all three muscle types. Fig. 3 . Rapamycin increases Ca 2+ -sensitivity of steady-state isometric force in (A) rabbit psoas fibers (1 µM rapamycin; N=6); (B) rabbit cardiac trabeculae (1 µM rapamycin; N=6); and (C) rat cardiac trabeculae (100 µM rapamycin; N=8). Each point represents the average force, normalized to that obtained at pCa 5 in the same muscle preparation. Error bars represent the standard error. The curves were generated from the Hill equation (Eq. 1), using average values of pCa 50 and n (Table 1) obtained by nonlinear least squares fits to the data from each fiber. Significance is expressed as * p < 0.05 and ** p < 0.01, when compared to the averaged control speed. Motility assays were conducted with F-actin and HMM from rabbit skeletal muscle. Isometric force is expressed as a ratio normalized to the pre-rapamycin control force for each individual muscle type. # Values (mean + SEM; N = 6 for rabbit skeletal and cardiac, N = 8 for rat cardiac) were obtained from Hill fits to data from individual muscle preparations. Significance is expressed as * p < 0.05, when compared to 0 µM rapamycin.
